AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 7 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Patients with breast, ovarian, or non-small cell lung cancer were able to develop T-cell immunity to HER-2/neu protein, according to a report in the Journal of Clinical Oncology.
In order to be successful, therapeutic vaccines to treat cancer often must avoid the development of tolerance to antigenic self-proteins such as the MAGE and gp100 proteins expressed by melanoma cells. Some cancers (e.g., breast and ovarian) contain cells that overexpress the nonmutated antigenic HER-2/neu protein.
Mary L. Disis, at the University of Washington in Seattle, and her colleagues hypothesized that "immunizing patients with subdominant peptide epitopes derived from HER-2/neu, using an adjuvant known to recruit professional antigen-presenting cells, granulocyte-macrophage colony-stimulating factor, would result in the generation of T-cell immunity specific for the HER-2/neu protein."
For the study, the investigators chose 64 patients with breast, ovarian, or non-small cell lung cancer that exhibited overexpression of the HER-2/neu protein. The subjects were inoculated intradermally with a vaccine containing peptides obtained from epitopes of the HER-2/neu protein combined with granulocyte-macrophage colony-stimulating factor.
Subjects underwent testing for antigen-specific T-cell immunity in peripheral-blood mononuclear cells at enrollment and before and after vaccination. Immunological data were reported only for the 38 subjects who completed a course of 6 vaccinations (Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu pep-tide-based vaccines. J Clin Oncol, 2002;20(11):2624-2632).
T-cell immunity to HER-2/neu peptides ...